Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer's screening

This article was originally published in The Gray Sheet

Executive Summary

Results of the Oxford Project to Investigate Memory and Aging (OPTIMA) study, a joint effort between Bristol-Myers Squibb and Oxford University, show that use of single photon emission computed tomography (SPECT) with Amersham's Ceretec and computed tomography detected Alzheimer's disease "in 90% of cases with a 97% specificity," the university reports May 25. Cortical parietotemporal hypoperfusion shown by SPECT uncovered 95% of the study's 78 autopsy-confirmed Alzheimer's patients, with 87.5% specificity. X-ray CT measurements of medial temporal lobe atrophy alone detected 92.5% of cases with 93% specificity. Overall, "195 patients with dementia and 95 controls" are being followed
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel